NHS Framework for the NHS London Region, Branded Medicines – Tranche A plus Cytokine Modulators and other Products, and Dolutegravir/Lamivudine

Descriptions

NHS framework for the NHS London Region, Branded Medicines – Tranche A, Annual Tranche — Cytokine Modulators and other products, and Dolutegravir/LamivudineOffer reference number: CM/PHR/16/5516CM/PHR/16/5516/01 – London Tranche A – 1 September 2020 to 31 August 2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/16/5516/02 – London Annual Tranche — Cytokine Modulators and other products — 1 September 2020 to 31 August 2021 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 months.CM/PHR/16/5516/03 – NHS framework agreement for the supply of Dolutegravir/Lamivudine — North of England – 1 September 2020 — 28 February 2021, South of England – 1 September 2020 — 31 August 2021, Midlands and East – 1 September 2020 — 28 February 2022, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.